This article was downloaded by: On: *26 January 2011* Access details: *Access Details: Free Access* Publisher *Taylor & Francis* Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK



Liquid Crystals

Publication details, including instructions for authors and subscription information: http://www.informaworld.com/smpp/title~content=t713926090

Heterotrimeric liquid crystalline thiadiazole derivatives

Kerstin Zab^a; Detlev Joachimi^a; Eva Novotna^b; Siegmar Diele^b; Carsten Tschierske^a ^a Martin-Luther-University Halle, Department of Chemistry, Institute of Organic Chemistry, Halle/Saale, Germany ^b Martin-Luther-University Halle, Department of Chemistry, Institute of Physical Chemistry, Halle/Saale, Germany

To cite this Article Zab, Kerstin , Joachimi, Detlev , Novotna, Eva , Diele, Siegmar and Tschierske, Carsten(1995) 'Heterotrimeric liquid crystalline thiadiazole derivatives', Liquid Crystals, 18: 4, 631 – 637 **To link to this Article: DOI:** 10.1080/02678299508036667 **URL:** http://dx.doi.org/10.1080/02678299508036667

PLEASE SCROLL DOWN FOR ARTICLE

Full terms and conditions of use: http://www.informaworld.com/terms-and-conditions-of-access.pdf

This article may be used for research, teaching and private study purposes. Any substantial or systematic reproduction, re-distribution, re-selling, loan or sub-licensing, systematic supply or distribution in any form to anyone is expressly forbidden.

The publisher does not give any warranty express or implied or make any representation that the contents will be complete or accurate or up to date. The accuracy of any instructions, formulae and drug doese should be independently verified with primary sources. The publisher shall not be liable for any loss, actions, claims, proceedings, demand or costs or damages whatsoever or howsoever caused arising directly or indirectly in connection with or arising out of the use of this material.

Heterotrimeric liquid crystalline thiadiazole derivatives

by KERSTIN ZAB, DETLEV JOACHIMI, EVA NOVOTNA[†], SIEGMAR DIELE[†], and CARSTEN TSCHIERSKE^{*}

Martin-Luther-University Halle, Department of Chemistry, Institute of Organic Chemistry, D-06015 Halle/Saale, Weinbergweg 16, Germany † Martin-Luther-University Halle, Department of Chemistry, Institute of Physical Chemistry, D-06099 Halle/Saale, Mühlpforte 1, Germany

(Received 29 July 1994; accepted 15 September 1994)


Various trimeric co-oligomers combining 2-phenyl-1,3,4-thiadiazole mesogenic moieties with a biphenyl mesogenic moiety were synthesized and their mesomorphic behaviour investigated by polarizing microscopy, calorimetry and X-ray scattering. Such co-oligomeric structures provide an opportunity to combine different mesogenic units. Thus readily accessible homochiral biphenyl mesogenic units were connected with thiadiazole mesogenic units leading to an oligomeric liquid crystal material with ferroelectric properties.

1. Introduction

The properties of polymeric liquid crystals depend strongly on the degree of polymerization, which often causes unsatisfactory reproducibility. This drawback could probably be circumvented by oligomers with a well-defined molecular structure. The first examples of such compounds were cyclic phosphazenes and the tetrameric liquid crystals based on biphenyl, bicyclohexyl, and phenylcyclohexyl mesogenic groups linked to a pentaerythritol central unit [1]. More recently homooligomeric 4-cyanobiphenyl derivatives and Shiffs bases have been described [2,3]. We have reported homotrimeric and homotetrameric oligomers incorporating thiadiazole rigid cores [4], and some of these compounds were found to form a broad smectic C phase.

It should be possible to influence the properties of such materials by combining them with other mesogenic units. Therefore we have synthesized trimeric co-oligomers by linking the 2-phenyl-1,3,4-thiadiazole system to different biphenyl mesogenic units.

At first we were especially interested in the investigation of the influence of the chemical structure of the mesogenic groups on the types of mesophase formed. Therefore cyanobiphenyl derivatives 1 a-d, phenylpyrimidine derivative 2 b, and 4-benzyloxybiphenyl derivatives 2 a and 2 c were synthesized and investigated. However, the major aim of our work was to obtain co-oligomers with a ferroelectric smectic C phase. Therefore the chiral biphenyl derivatives 3 and 4 were synthesized.




2. Synthesis

The co-oligomers 1a-1d combining 2-phenyl-1,3,4thiadiazole and 4-cyanobiphenyl units were obtained according to scheme 1 which gives the synthesis of compound 1c as a representative example. Etherification of 4'-cyano-4-hydroxybiphenyl with 2,2-dimethyl-5-(4hydroxybutyl)-1,3-dioxolane 6 in the presence of triphenylphosphine and DEAD (diethyl azodicarboxylate) [5] gave the precursor 7 from which 6-(4'-cyanobiphenyl-4-yloxy)-hexan-1,2-diol 8 was obtained by hydrolytic acetal cleavage [6]. The N,N-dicyclohexylcarbodiimide mediated esterification of 8 with bromovaleric acid yielded compound 9 which finally was etherified with 4-(5-undecyl-1,3,4-thiadiazol-2-yl)phenol to give 1c. Compounds 1a, 1b, 1d and the homotrimer 5 (see table 3) were synthesized in an analogous manner.

In order to obtain ferroelectric liquid crystalline materials, we combined two 2-phenyl-1,3,4-thiadiazole mesogenic units with a homochiral biphenyl mesogen (20). (The designation of the configuration as (R) or (S) corresponds only to the homochiral part of the molecule.

^{*} Author for correspondence.




Scheme 1. Synthesis of 1,2,-bis-5-[4-(5-undecyl-1,3,4-thiadiazol-2-yl)phenoxy]pentanoyloxy}-6-(4'-cyanobipenyl-4yloxy)hexane (1 c).


The 1,2-diol units were racemic in all cases.) The synthesis was designed in such a way that the homochiral compound could be used close towards the end of the reaction cascade (see scheme 2). The Pd-catalysed cross coupling reaction [7,8] of the 4-benzyloxyphenylboronic acid 12 [9,10] with the aryl bromide 13 gave the dioxolane derivative 14, which afterwards was deprotected [6]. The resulting 6-(4'-benzyloxybiphenyl-4-yloxy)hexan-1,2-diol 15 was esterified with various aryloxypentanoic acids 16 a-c, using the carbodiimide method, to yield the co-oligomers 2 a-c. In order to get a precursor for chiral derivatives, 14 was debenzylated. It turned out that the hydrogenolysis gave a mixture of the desired product 18 and, owing to the partial cleavage of the acetonide group, also compound 17. The diol-group of 17 was reprotected by reacting it with 2,2-dimethoxypropane in the presence of pyridinium tosylate [11, 12]. Mitsunobu etherification [5] of 18 with (S)-(+)-octan-2-ol followed by the removal of the acetonide group gave the diol 20 which afterwards was esterified with 5-[4-(5-heptyl-1,3,4-thiadiazol-2-yl)phenoxy]pentanoic acid to give the final product 3. The compounds 4 can be prepared using analogous procedures.

3. Discussion of transition temperatures

The liquid crystalline behaviour of the co-oligomers **1 a-d** incorporating 2-phenyl-1,3,4-thiadiazole and 4cyanobiphenyl units is given in table 1. Comparison of the



- Scheme 2. Synthesis of (R)-1,2-bis-{5-[4-(5-heptyl-1,3,4-thiadiazol-2-yl)phenoxy]pentanoyloxy}-6-[4'-(oct-2-yloxy)biphenyl-4-oxy]hexane (3).
- Table 1. Phase transition temperatures (°C) and enthalpies $(\Delta H/kJ \text{ mol}^{-1})$ in parentheses of compounds **1 a–d** with 2-phenyl-1,3,4-thiadiazole and 4-cyanobiphenyl as mesogenic units.



cyanobiphenyl derivatives **1 a–d** with the homotrimer **5** [4] (see table 3) shows that the replacement of only one thiadiazole unit by a cyanobiphenyl unit suppresses the smectic C phase and gives rise to the formation of an enantiotropic smectic A phase. Variations of the lengths

NC




Figure 1. DSC heating and cooling traces (5 K min⁻¹) for compound 1 c.

of the spacers as well as the side chains have no influence on the phase type. The differences in the melting and clearing temperatures are only small. Supercooling of the mesophases is possible down to 18°C (1 b), 32°C (1 c) and 36°C (1 d). In this temperature range spontaneous crystallization occurs for all the compounds with the exception of **1 a** which only crystallized partly after several months of storage at room temperature. The DSC traces of this compound revealed a glass transition of 5°C (see figure 1). The transition temperatures of the 'mixed' trimers consisting of a 4-benzyloxybiphenyl rigid core and two other heterocyclic mesogenic units are given in table 2. Contrasting compounds 2a, 2b, and 2c shows that the mesomorphic behaviour of these oligomers is strongly influenced by the type of heteroaromatic ring incorporated. It is obvious that replacing the thiadiazole ring of compound 2 a by a pyrimidine ring (2 b) leads to the loss of the smectic C phase, whereas the three-ring thiadiazole derivative 2c exhibits an S_C–N polymorphism with high mesophase stability. It is remarkable that the replacement of the bent 2-phenylthiadiazole unit by a linear 2phenylpyrimidine core gives rise to a decrease in the clearing temperature. If one compares other calamitic liquid crystalline compounds incorporating thiadiazole or pyrimidine units, the reverse order of mesophase stability is usually observed.

The trimers 1 a, 2 a, 3, 4 and 5 which are summarized in table 3 consist of a pair of 4-(5-heptyl-1,3,4-thiadiazole-2-yl)phenoxy mesogenic units linked via flexible spacers to a central unit and a third structurally different calamitic unit. The comparison of these compounds with the homotrimeric compound 5 shows that it is possible to retain the smectic C phase. In the case of the homochiral compound 3, a bistable switchable ferroelectric smectic C* phase was detected, but the measured value of the spontaneous polarization was very small (0.5 nC cm⁻² at 72°C). Unfortunately, if the biphenyl core carries a polar substituent such as an (R)-1-(ethoxycarbonyl)ethyl group (4), the S_C phase is replaced by a S_A phase.

Preliminary X-ray studies of the liquid crystalline phases of 1c, 2a and 2b have been performed using the Guinier method. In all cases, a layer structure without order in the layers has been formed. The classification as S_A or S_C could not be obtained by means of the X-ray studies since oriented samples could not be obtained. This was established by investigations of the textures between crossed polarizers. Comparison between the layer thickness and the molecular length shows that for all the substances investigated so far, the layer periods of the smectic phases (1 c: d = 2.58 nm; 2 a: d = 2.10 nm; 2 b: d = 2.45 nm) correspond with the averaged values of the lengths of the single calamitic moieties and do not correspond with the total lengths of the molecules in a tuning fork like conformation (1 c: L = 4.0 mm; 2 a: L = 4.45 nm; **2 b**: L = 4.6 nm). Therefore an intercalation of the branched molecules must be assumed.

The molecular model of compound **2b** in this tuning fork-like conformation is given in figure 2.

4. Experimental

4.1. General considerations

¹H NMR spectra were recorded on a Bruker WP-200 or an AC-80 spectrometer with tetramethylsilane as internal standard. IR spectra were recorded by using a Specord 71 IR spectrometer. Transition temperatures were measured using a Mettler FP82 HT hot stage and control unit, in conjunction with a Nikon Optiphot-2 polarizing microscope, and confirmed using differential scanning calorimetry (Perkin-Elmer DSC-7). Mass spectra were recoreded on an AMD 402 mass spectrometer (70 eV). Thin-layer chromatography was performed on TLC aluminium sheets (silica gel 60 F₂₅₄) from Merck and visualized by UV-light or by using a spray-solution of 3',3"-dibromothymolsulphonaphthalene in aqueous KOH and devloping with NH₃. Silica gel 60 (0, 063-0, 200) from Merck was used for column chromatography. Solvents were purified and dried according to standard procedures [14]. The syntheses of compounds 1 c, 2 b, and 3 are given as representative examples of the experimental procedures used.

4.2. Synthesis of 1,2-bis-{5-[4-(5-undecyl-1,3,4-thiadiazol-2-yl)phenoxy]pentanoyloxy-6-(4'-cyanobiphenyl-4-yloxy)hexane (1 c)

4.2.1. 1,2-bis-(5-Bromopentanoyloxy)-6-(4'-cyanobiphenyl-4-yloxy)hexane (9)

N,N-Dicyclohexylcarbodiimide (0.7 g, 3.45 mmol) was added to a stirred, cooled (0°C) solution of 6-(4'-

Table 2. Phase types, phase transition temperatures (°C) and enthalpies $(\Delta H/kJ \text{ mol}^{-1})$ in parentheses of compounds **2a**-c with a 4-benzyloxybiphenyl unit.

$-CH_2O$ $-$												
2	R	С		Sx		Sc		SA		N		I
a	N−N —(' _S ')—C ₇ H ₁₅	•	115 (65·8)	(•	84 (9·3)	٠	110) (23·6)					•
b.	⟨N	•	106 (53·5)		—			(•	100) (9·3)			•
с.		٠	149 (59·9)			•	197 (9·1)			•	206 (4·5)	•

Table 3. Phase types, phase transition temperatures (°C) and enthalpies ($\Delta H/kJ \text{ mol}^{-1}$) in parentheses of compounds 1 a, 2 a, 3, 4 and 5 with different mesogenic units.

$ \begin{array}{c} OOC \cdot (CH_2)_4 - O - \swarrow & \bigvee_{S} \\ & & & & \\ OOC - (CH_2)_n - & & & \\ & & & \\ OOC - (CH_2)_4 - O - & & & \\ & & & \\ & & & \\ OOC - (CH_2)_4 - O - & & & \\ & & & & \\ & & & \\ & & & \\ & & & \\ & & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & $													
$-OOC-(CH_2)_4 - O - (CH_2)_4 - O - (S^{-N-N}_{-N-N})_{-N-N}$													
Compoun	d R	n	С		Sx		S _C		S _A		Ι		
1 a		4	•	58 (38·5)		_			•	122 (19·6)	•		
2 a	СН₂-0 -	4	٠	115 (65·8)	(•	84 (9·3)	•	110) (23·6)			•		
3	H ₁₂ C ₆ ¢H-O-	4	•	92 (76·6)		—	(S _C *	82) (16·7)		—	•		
4	н₅с₂оо-çн-о- сн₃	1	•	90 (27·3)		—		—	(•	43) (5·2)	•		
5	H ₁₅ C ₇ −ℓ∕ _S ,∕∕	4	٠	109 (102-8)			(•	92) (22·6)			•		

cyanobiphenyl-4-yloxy)hexan-1,2-diol **8** [15] (0.46 g, 1.5 mmol), 5-bromovaleric acid (0.57 g, 3.15 mmol) and a catalytic quantity of 4-N,N-dimethylaminopyridine in 10 ml of dry dichloromethane. The mixture was stirred at room temperature for 24 h. After complete reaction the mixture was filtered, the solvent was removed *in vacuo* and the residue was dissolved in dichloromethane. The

organic phase was washed successively with aqueous sodium hydrogen carbonate $(3 \times)$, 10 per cent hydrochloric acid and water. Afterwards, the solution was dried (Na₂SO₄) and the solvent removed *in vacuo*. The product was used as obtained after purification by column chromatography using chloroform/methanol (10:2) as eluent. Yield: 0.45 g (45 per cent).




Figure 2. Molecular model of compound **2b** in a tuning fork-like conformation (CERIUS 3.2).

4.2.2. 1,2-bis-{5-[4-(5-Undecyl-1,3,4-thiadiazol-2-yl)phenoxy]pentanoyloxy}-6-(4'-cyanobiphenyl-4-yloxy)hexane (1c)

A mixture of compound 9 (0.43 g, 0.68 mmol), 4-(5-undecyl-1,3,4-thiadiazol-2-yl)phenol [13] 10 (0.5 g 1.4 mmol), anhydrous potassium carbonate (1 g, 7 mmol) and potassium iodide (50 mg) in 10 ml of diethyl ketone was stirred and heated at reflux under an argon atmosphere for 30 h. After the reaction was finished, the solvent was removed in vacuo and chloroform was added to the residue. The organic phase was filtered and washed with 10 per cent hydrochloric acid, aqueous sodium hydrogen carbonate and water. The solution was dried (Na₂SO₄). before the solvent was removed in vacuo to give the crude product which was recrystallized from acetone. Yield: 0.2 g (29 per cent); C 54 SA 103 I. Elemental analysis (per cent): Found (calculated for $C_{67}H_{89}O_7N_5S_2$): C, 70.27 (70.55); H, 7.88 (7.86); N, 6.17 (6.14); S, 5.69 (5.62), ¹H NMR, δ ppm, CDCl₃: 0.85 (t, 6 H, -CH₃), 1.23-1.60 (m, 36 H, $-CH_{2}$), 1.78–1.82 (m, 14 H, $-CH_{2}$), 2.38 (t, broad, 4H, $-OOC-CH_{2}$ -), 3.03 (t, 4H, thiadiazole-CH₂-), 3.92-4.06 (m, 6H, $-OCH_2-$), 4.26 (dd, 2H, $-CH_2-$ OOC-), 5.08-5.13 (m, 1H, (-CH-OOC-), 6.90 (d, 4H,

H-ar.), 6.94 (d, 2 H, H-ar.), 7.48 (d, 2 H, H-ar.), 7.59 (d, 2 H, H-ar.), 7.66 (d, 2 H, H-ar.), 7.81 (d, 4 H, H-ar.).

4.3. Synthesis of (R)-1,2-bis-{5-[4-(5-heptyl-1,3,4-thiadiazol-2-yl)phenoxy]pentanoyloxy}-6[4'-(1-methylheptyloxy)biphenyl-4-yloxy] hexane (3)

4.3.1. 4-Benzyloxyphenylboronic acid (12)

A solution of *n*-butyl lithium (2.5 M solution in hexane, 23.7 ml, 0.06 mol) was added dropwise to a stirred and cooled $(-78^{\circ}C)$ solution of 4-bromophenyl benzyl ether 11 (10.6 g, 0.04 mol) [11] in 50 ml of dry THF under dry argon. This mixture was stirred for 2 h at -78° C. Then a solution of trimethyl borate (13.6 ml), 0.12 mol) in 15 ml of dry THF (cooled to -30° C) was added at this temperature with stirring. After 1 h at -78° C, the temperature was allowed to rise to room temperature overnight. The mixture was hydrolyzed with 50 ml of 10 per cent hydrochloric acid at 0°C and was stirred at room temperature for 1 h. The product was extracted into ethyl acetate, and the combined organic extracts were washed with aqueous sodium hydrogen carbonate and water. After the solution had been dried (Na_2SO_4) , the solvent was removed in vacuo and the residue was treated with boiling methanol. The solution was cooled and the precipitate was filtered with suction. The methanol was removed by evaporation and the monomeric 4-benzyloxyphenylboronic acid was recrystallized from petroleum ether/ethyl acetate (10:1) [7,8]. Yield: 5.3 g (58 per cent); m.p. 196°C. Elemental analysis (per cent): Found (calculated for C₁₃H₁₃O₃B): C, 68·63 (68·46); H, 5·70 (5·74) IR, v cm⁻¹, (nujol): 3520–3235 (OH). ¹H NMR, δ ppm, DMSO: 5.1 (s, 2H, -CH₂-O-), 6.95 (d, 2H, H-ar.), 7.30-7.45 (m, 5 H, H-ar.), 7.71 (d, 2 H, H-ar.), 7.83 (s, 2 H, -OH). MS m/z (rel. intensity, per cent): 228 (M⁺) (11), 91 (100), 65 (11).

4.3.2. 2,2-Dimethyl-4-(4'-benzyloxybiphenyl-4-yloxybutyl)-1,3-dioxolane (14)

A solution of compound **12** (4.5 g, 19 mmol) in 40 ml of ethanol was added to a stirred mixture of compound **13** (4.8 g, 14 mmol) and tetrakis(triphenylphosphine)-palladium (0) (0.75 g, 0.65 mmol) [12] in 80 ml of benzene and 80 ml of 2 M aqueous sodium carbonate at room temperature under a dry argon atmosphere. The thoroughly stirred mixture was heated under reflux for 14 h. The product was extracted into dichloromethane and the combined organic extracts were washed with brine and dried (Na₂SO₄). The solvent was removed *in vacuo* and the residue was purified by column chromatography using chloroform/methanol (10:0-5) as eluent and finally recrystallized from methanol [7]. Yield: 3 g (50 per cent); m.p. 136°C. Elemental analysis (per cent): Found (calculated for C₂₈H₃₂O₄): C, 77.80 (77.74); H, 7.36 (7.45).

¹H NMR, δ ppm. CDCl₃: 1·34 (s, 3 H, –CH₃), 1·39 (s, 3 H, –CH₃), 1·54–1·64 (m, 4 H, –CH₂–), 1·79–1·85 (m, 2 H, –CH₂–), 3·51 (dd, 1 H, –O–C<u>H</u>₂–CH–, H_{ax}), 3·95–4·10 (m, 4 H, –OCH₂–, –CH–, –O–C<u>H</u>₂–CH–, H_{eq}), 5·08 (s, 2 H, –CH₂–O–), 6·91 (d, 2 H, H–ar.), 7·0 (d, 2 H, H–ar.), 7·30–7·47 (m, 9 H, H–ar.). MS *m/z* (rel. intensity, per cent): 432 (M⁺) (29), 366 (14), 185 (11), 99 (21), 91 (100), 81 (14), 43 (14).

4.3.3. 6-(4'-Hydroxybiphenyl-4-yloxy)hexan-1,2-diol (17)

A mixture of compound 14 (3.95 g, 9 mmol) and palladium on charcoal (0.5 g, 0.45 mmol) in 150 ml of ethyl acetate was shaken for 1 to 2 d in a hydrogen atmosphere. After complete reaction, the mixture was filtered, the methanol was removed by evaporation and the crude product was purified by recrystallization from dichloromethane. Yield: 2 g (73 per cent); C 140 S_C 183 I. ¹H NMR, δ ppm, DMSO: 1.08–1.68 (m, 6H, –CH₂–), 3.04–3.32 (m, 3 H, –C<u>H</u>₂–OH, –OH), 3.84 (t, 2 H, –OCH₂–), 4.24–4.36 (m, 2 H, –C<u>H</u>–OH, –O<u>H</u>), 6.64 (d, 2 H, H–ar.), 6.80 (d, 2 H, H–ar.), 7.24 (d, 2 H, H–ar.), 7.32 (d, 2 H, H–ar.), 9.28 (s, 1 H, –OH). MS *m/z* (rel. intensity, per cent): 302 (M +) (16), 186 (100), 85 (14).

4.3.4. 4-(4'-Hydroxybiphenyl-4-yloxy)butyl-2,2-dimethyl-1,3-dioxolane (**18**)

The crude product **17** (2 g, 6.6 mmol) and 2,2dimethoxypropane (8 ml, 66 mmol) in 20 ml of dry acetone was stirred at room temperature for 24 h in the presence of a catalytic quantity of pyridinium tosylate [16, 17]. Afterwards, the solvent and the excess of 2,2-dimethoxypropane were removed *in vacuo*. The precipitate was dissolved in ethyl acetate and the organic phase was washed successively with aqueous sodium hydrogen carbonate and water. After drying the solution (Na₂SO₄), the solvent was removed *in vacuo*. The product was separated by column chromatography (R_f : 0.49) using chloroform/methanol (10:0.5) as eluent. The resulting yellow oil was used as the crude material in the next step. Yield: 1.4 g (63 per cent).

4.3.5. (*R*)-4-[4'-(*Oct*-2-yloxy)biphenyl-4-yloxy]butyl-2,2-dimethyl-1,3-dioxolane (**19**)

DEADC (1.5 ml, 10 mmol) was added to a stirred solution of **18** (2.3 g, 6.7 mmol), (S)-(+)-octan-2-ol (1.5 ml, 10 mmol) and dry triphenylphosphine (2.6 g, 10 mmol) in 15 ml of dry THF at 0°C [5]. Afterwards, the mixture was stirred at room temperature overnight. The solvent was removed *in vacuo* and the residue was dissolved in cold dry ether. The precipitate was filtered with suction, washed with ether and the solvent evapo-

rated. The crude product was recrystallized from methanol/water (10:1) to yield colourless crystals. Yield: 1.6 g (54 per cent); m.p. 40°C. Elemental analysis (per cent): Found (calculated for C₂₉H₄₂O₄): C, 76·37 (76·60); H, 9·26 (9·31). ¹H NMR, δ ppm, CDCl₃: 0·83 (t, 3 H, -CH₃, 1·29 (d, 3 H, -CH-C<u>H</u>₃), 1·34 (s, 3 H, CH₃), 1·40 (s, 3 H, CH₃), 1·53–1·82 (m, 16 H, -CH₂–), 3·51 (dd, 1 H, -O-C<u>H</u>₂–CH–, H_{ax.}), 3·97–4·06 (m, 4 H, -OCH₂–, -O-C<u>H</u>–CH₂–, -O-C<u>H</u>₂–CH–, H_{cq.}), 4·30–4·36 (m, 1 H, -C<u>H</u>–CH₃), 6·90 (d, 4 H, H–ar.), 7·43 (m, 4 H, H–ar.). MS *m/z* (rel. intensity, per cent): 454 (M⁺) (46), 342 (29), 186 (100), 99 (66), 81 (40), 55 (14), 43 (48).

4.3.6. (*R*)-6-[4'-(*Oct-2-yloxy*)biphenyl-4-yloxy]hexan-1,2-diol (**20**)

Compound **19** (1.4 g, 3 mmol) was heated under reflux in 50 ml of a methanol/water (10:1) mixture in the presence of a catalytic quantity pyridinium tosylate for 3 h [6]. On cooling the solution to room temperature, the product crystallized. The crystals were filtered off, recrystallized once from methanol/water (10:1) and used as such in the next step. Yield: 0.7 g (58 per cent); C 97 S_A 112 I. ¹H NMR, δ ppm, DMSO: 0.80 (t, 3 H, -CH₃), 1.18–1.80 (m,19 H, -CH-CH₃, -CH₂-), 3.26 (d, 2 H, -CH₂-OH), 3.36–3.44 (m, 1 H, -O-CH-CH₂-), 3.89– 4.04 (m, 4 H, -OCH₂-, -OH), 4.34–4.37 (m, 1 H, -CH-CH₃), 6.90 (m, 4 H, H-ar.), 7.43 (m, 4 H, H-ar.). MS *m/z* (rel. intensity, per cent): 414 (M⁺) (4), 330 (29), 214 (92), 186 (100), 157 (13), 85 (20).

4.3.7. (*R*)-1,2-bis-{5-[4-(5-Heptyl-1,3,4-thiadiazol-2yl)phenoxy]pentanoyloxy}-6-[4'-(oct-2-yloxy)biphenyl-4-oxy]hexane (**3**)

The same experimental procedure as described for the preparation of 9 was used. Quantities: N,N-dicyclohexylcarbodiimide (0.23 g, 1.1 mmol), 5-[4-(5-heptyl-1,3,4thiadiazol-2-yl)phenoxy]pentanoic acid (16 a) (0.38 g, 1 mmol), compound 20 (0.2 g, 0.48 mmol) and a catalytic quantity of 4-N, N-dimethylaminopyridine in 10 ml of dry dichlormethane. The residue was purified by recrystallization from acetone. Yield: 0.35 g (66 per cent); C 93 (S^{*}_c 79) I. 'HNMR, δ ppm, CDCl₃: 0.76 (t, 9 H, -CH₃), 1.12-1.40 (m, 29 H, -CH₂-, -CH-CH₃), 1.65-1.75 (m, 18 H, -CH₂-), 2.36 (t.broad, 4H, -COO-CH₂--), 3.0 (t, 4H, thiadiazole-CH2-), 3.82-4.05 (m, 7H, -OCH2-, -CH-CH₃), 4·20 (dd, 2H, -CH-CH₂-), 5·04-5·16 (m, 1H, (-CH-OOC-), 6.8 (m, 8H, H-ar.), 7.36 (d, 4H, H-ar.), 7.72 (d, 4 H, H-ar.). MS m/z (rel. intensity, per cent): 1125 (32), 1016 (16), 946 (16), 754 (80), 642 (48), 457 (38), 376 (32), 359 (53), 305 (36), 292 (75), 276 (30), 205 (30), 192, (71), 186 (100), 81 (33), 55 (48).

4.4. Synthesis of 1,2-bis-{5-[4-(5-heptylpyrimidin-2-yl)phenoxy]pentanoyloxy}-6-(4'-benzyloxybiphenyl-4yloxy)hexane (2 b)

4.4.1. 6-(4'-Benzyloxybiphenyl-4'-yloxy)hexane-1,2diol (15)

Compound 14 (1.0 g, 2.3 mmol) was heated under reflux in 50 ml of methanol/water (10:1) after the addition of 10 per cent hydrochloric acid (5 ml). After complete reaction, the solvent was removed *in vacuo* and chloroform was added to the residue. The mixture was heated to reflux temperature and filtered while hot. Upon cooling the chloroform solution, the product crystallized. Yield: 0.75 g (83 per cent), m.p. 193°C. IR $v \text{ cm}^{-1}$, (nujol): 3465–3100 (OH). MS m/z (rel. intensity, per cent): 392 (M⁺) (68), 301 (16), 276 (11), 185 (100), 91 (58).

4.4.2. 1,2-bis-{5-[4-(5-Heptylpyrimidin-2-yl)phenoxy]pentanoyloxy}-6-(4'-benzyloxybiphenyl-4-yloxy)hexane (2 b)

The experimental procedure used was the same as that described for the preparation of 9. Quantities: compound 0.18 mmol), 5-[4-(5-heptylpyrimidin-2-15 (70 mg, yl)phenoxy]pentanoic acid 16b (150 mg, 0.41 mmol), a catalytic amount of DMAP, DCC (90 mg, 0.43 mmol) and dry dichloromethane (10 ml). The crude product was purified by column chromatography (R_f : 0.87) using chloroform/methanol (10:1) as eluent and recrystallized from methanol/chloroform. Yield: 80 mg (42 per cent); C 106 (S_A 100) I. ¹HNMR, δ ppm, CDCl₃: 0.85 (t, 6H, -CH₃), 1·15-1·40 (m, 14 H, -CH₂-), 1·49-1·71 (m, 10 H, -CH₂-), 1.71-1.88 (m, 4 H, pyrimidine-CH₂-), 3.90-4.01 $(m, 6 H, -OCH_2-), 4.27 (dd, 2 H, -CH-CH_2-), 5.06 (s, 2 H, -CH-CH_2$ -CH₂O-), 5·08-5·19 (m, 1 H, -CH-CH₂-), 6·84-7·15 (m, 8H, H-ar.), 7·29-7·48 (m, 9H, H-ar.), 8·29 (d, 4H, H-ar.), 8.52 (s, 4 H, H-pyrimidine). MS m/z (rel. intensity, per cent): 1091 (M⁺), 551 (18), 368 (41), 313 (37), 236 (28), 185 (18), 135 (23), 123 (33), 109 (53), 95 (88), 83 (100), 57 (95).

This work was kindly supported by the Fonds der Chemischen Industrie, the Bundesministerium für Forschung und Technologie (BMFT) and by the BASF AG, Ludwigshafen.

References

- ALLCOCK, H. R., and KIM, C., 1989, *Macromolecules*, 22, 2596. EIDENSCHINK, R., KREUTZER, F. H., and DE JEU, W. H., 1990, *Liq. Crystals*, 8, 879.
- [2] BACH, V., BECK, K., ETZBACH, K. H., SIEMENSMEYER, K., and WAGENBLAST, G., 1992, 21st Freiburger Arbeitstagung Flüssigkristalle, p. 40.
- [3] ATTARD, G. S., DOUGLASS, A. G., IMRIE, C. T., and TAYLOR, L., 1992, *Liq. Crystals*, 11, 779.
- [4] ZAB, K., AGERT, O., JOACHIMI, D., NEUMANN, B., TSCHIERSKE, C., 1995, Liq. Crystals, 18, 489.
- [5] MITSUNOBU, O., 1981, Synthesis, p. 1.
- [6] VAN RUSBERGEN, R., ANTEUNIS, M. J. O., and DEU BRUYN, A., 1983, J. Carbohydr. Chem., 2, 395.
- [7] GRAY, G. W., HIRD, M., and TOYNE, K. J., 1991, Molec. Crystals liq. Crystals, 195, 221.
- [8] HIRD, M., GRAY, G. W., and TOYNE, K. J., 1991, Molec. Crystals liq. Crystals, 206, 187.
- [9] GRAY, G. W., HIRD, M., LACEY, D., and TOYNE, K. J., 1989, J. chem. Soc. Perkin Trans. II, p. 2041.
- [10] PERCEC, V., and JOHANSSON, G., 1993, J. mater. Chem., 3, 83.
- [11] POWFLL, S. G., and ADAMS, R., 1920, J. Am. chem. Soc., 42, 646.
- [12] COULSON, D. R., SATEK, L. C., and GRIM, S. O., 1972, *Inorg. Synth.*, 13, 121.
- [13] TSCHIERSKE, C., and GIRDZIUNAITE, D., 1991, J. prakt. Chem., 333, 135.
- [14] FURNISS, B. S., HANNAFORD, A. J., SMITH, P. W. G., and TATCHELL, A. R., 1989, Vogel's Textbook of Practical Organic Chemistry, 5th edition (Longman Scientific & Technical, Essex), p. 395.
- [15] JOACHIMI, D., TSCHIERSKE, C., MÜLLER, H., WENDORFF, J. H., SCHNEIDER, L., and KLEPPINGER, R., 1993, Angew. Chem., 32, 1165.
- [16] SCHMIDT, T. O., 1963, Meth. Carbohydr. Chem., 2, 318.
- [17] DE BELDER, A. N., 1965, Adv. Carbohydr. Chem., 20, 219.